[225Ac]Ac-PSMA-617 Targeted Alpha Therapy in Metastatic Castration-Resistant Prostate Cancer: efficacy and treatment outcome

被引：0
|
作者：
Ebrahimifard, A. [1 ]
Bagheri, S. [1 ]
Wang, Q. [1 ]
Eilsberger, F. [1 ]
Luster, M. [1 ]
Librizzi, D. [1 ]
Yousefi, B. H. [1 ]
机构：
[1] Philipps Univ Marburg, Marburg, Germany
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2024年 / 51卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
OP-760
引用
收藏
页码：S360 / S360
页数：1
相关论文
共 50 条
  • [31] Survival outcomes of patients with metastatic castration resistant prostate cancer receiving 225Ac-PSMA-617 radioligand therapy
    Bal, Chandrasekhar
    Ballal, Sanjana
    Yadav, Madhav
    Sahoo, Ranjit
    Tripathi, Madhavi
    JOURNAL OF NUCLEAR MEDICINE, 2023, 64
  • [32] Long-Term Safety and Survival Outcomes of [225Ac]Ac-PSMA (Prostate-Specific Membrane Antigen) and [225Ac]Ac-/[177Lu]Lu-PSMA (TANDEM) Radioligand Therapy (PRLT) in Metastatic Castration-Resistant Prostate Cancer
    Perrone, Elisabetta
    Giordano, Alessandro
    Calcagni, Maria Lucia
    Leccisotti, Lucia
    Moretti, Roberto
    Eismant, Aleksandr
    Ghai, Kriti
    Parkar, Tanay
    Mishra, Aditi
    Heidenreich, Axel
    Wirtz, Ralph M.
    Mueller, Joerg
    Greifenstein, Lukas
    Baum, Richard P.
    CANCERS, 2025, 17 (03)
  • [33] AcTION: A phase 1 study of [225Ac]Ac-PSMA-617 in men with PSMA-positive prostate cancer with or without prior [177Lu]Lu-PSMA-617 radioligand therapy
    Sathekge, M.
    Crumbaker, M.
    Joshua, A. M.
    Bruchertseifer, F.
    Kreisl, T.
    Emineni, S.
    Wehbe, J.
    Korn, M.
    Morgenstern, A.
    Emmett, L.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (SUPPL 1) : S152 - S153
  • [34] 225Ac-PSMA-617 for Therapy of Prostate Cancer
    Kratochwil, Clemens
    Haberkorn, Uwe
    Giesel, Frederik Lars
    SEMINARS IN NUCLEAR MEDICINE, 2020, 50 (02) : 133 - 140
  • [35] Safety and efficacy of Ac-225-PSMA-617 in metastatic castration resistant prostate cancer (mCRPC) after failure of Lu-177-PSMA
    Tauber, R. L.
    Feuerecker, B.
    Knorr, K.
    Beheshti, A.
    Seidl, C.
    D'Alessandria, C.
    Bruchertseifer, F.
    Retz, M.
    Gschwend, J. E.
    Weber, W.
    Morgenstern, A.
    Eiber, M.
    ANNALS OF ONCOLOGY, 2019, 30
  • [36] Efficacy and Safety of [225Ac]Ac-PSMA-617 Augmented [177Lu]Lu-PSMA-617 Radioligand Therapy in Patients with Highly Advanced mCRPC with Poor Prognosis
    Rosar, Florian
    Krause, Jonas
    Bartholoma, Mark
    Maus, Stephan
    Stemler, Tobias
    Hierlmeier, Ina
    Linxweiler, Johannes
    Ezziddin, Samer
    Khreish, Fadi
    PHARMACEUTICS, 2021, 13 (05)
  • [37] Therapeutic efficacy of 225Ac-PSMA-617 targeted alpha therapy in patients of metastatic castrate resistant prostate cancer after taxane-based chemotherapy
    Ishita Sen
    Parul Thakral
    Priya Tiwari
    Vineet Pant
    Subha Shankar Das
    Divya Manda
    Vinod Raina
    Annals of Nuclear Medicine, 2021, 35 : 794 - 810
  • [38] Therapeutic efficacy of 225Ac-PSMA-617 targeted alpha therapy in patients of metastatic castrate resistant prostate cancer after taxane-based chemotherapy
    Sen, Ishita
    Thakral, Parul
    Tiwari, Priya
    Pant, Vineet
    Das, Subha Shankar
    Manda, Divya
    Raina, Vinod
    ANNALS OF NUCLEAR MEDICINE, 2021, 35 (07) : 794 - 810
  • [39] 213Bi-PSMA-617 targeted alpha-radionuclide therapy in metastatic castration-resistant prostate cancer
    Mike Sathekge
    Otto Knoesen
    Marian Meckel
    Moshe Modiselle
    Mariza Vorster
    Sebastian Marx
    European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44 : 1099 - 1100
  • [40] 213Bi-PSMA-617 targeted alpha-radionuclide therapy in metastatic castration-resistant prostate cancer
    Sathekge, Mike
    Knoesen, Otto
    Meckel, Marian
    Modiselle, Moshe
    Vorster, Mariza
    Marx, Sebastian
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 (06) : 1099 - 1100
12345